Nevertheless, insufficient statistical evidence was estimated for the risk of breast cancer recurrence for patients who were treated with aromatase inhibitors and using a topical hormonal treatment for vaginal symptoms like dryness at the same time. This evidence concerns the gene CYP19A1 and breast carcinoma.